GlassScriptPhysician profile
Kelly Block
NPI 1740786631
$1,506.78
in general payments reported to CMS, 2019-2025
15 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $257 · 2023: $375 · 2024: $74.34 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $362.53 | 2023-2025 | General - Dbs |
| Abbvie INC. | $316.96 | 2022-2025 | |
| Medtronic, INC. | $227.29 | 2023 | Percept PC Brainsense, Sensight |
| Acadia Pharmaceuticals INC | $225.74 | 2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $123.61 | 2022 | |
| Janssen Biotech, INC. | $39.09 | 2025 | |
| Csl Behring | $33.62 | 2022 | |
| Lilly USA, LLC | $32.86 | 2025 | Kisunla |
| Springworks Therapeutics, INC. | $29.36 | 2025 | Gomekli |
| Eisai INC. | $22.97 | 2025 | |
| Tanabe Pharma America, INC. | $20.56 | 2025 | Radicava |
| Pfizer INC. | $19.06 | 2025 | |
| Genentech USA, INC. | $18.14 | 2025 | Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $17.98 | 2025 | Symbravo |
| Vanda Pharmaceuticals INC. | $17.01 | 2024 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.